Coverage Initiated by Evercore ISI for Atara Biotherapeutics (NASDAQ:ATRA)

0
38

Stock analysts at Evercore ISI initiated coverage on shares of  Atara Biotherapeutics (NASDAQ:ATRA) in a report issued on Tuesday. The brokerage set a Outperform rating on the Medical stock. A price-to-earnings ratio of #N/A and a beta of 2.25. Atara Biotherapeutics has a twelve month low $4.52 of  and a twelve month high of $21.45.

Shares of Atara Biotherapeutics traded up $0.73 on Tuesday, reaching $14.57. 2497746 shares of the stock traded hands, compared to its average volume of 2307893. Shares of Atara Biotherapeutics closed trading at $14.57 on Tuesday mid-day. The firm’s 50 day moving average is $$10.60 and its 200 day moving average is $12.34.Atara Biotherapeutics  has a 12 month low of $13.83 and a 12 month high of $21.45. While on yearly highs and lows, Atara Biotherapeutics’s today has traded high as $14.67 and has touched $13.83 on the downward trend. See More Analyst Rating at: RATING

Atara Biotherapeutics Earnings and What to expect: 

Atara Biotherapeutics last released its earnings data on May 6th, 2020. The biotechnology company reported ($1.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.41) by $0.21. Atara Biotherapeutics has generated ($5.67) earnings per share over the last year. Atara Biotherapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, August 13th, 2020 based off prior year’s report dates.

Earnings for Atara Biotherapeutics are expected to grow in the coming year, from ($4.63) to ($4.35) per share. The P/E ratio of Atara Biotherapeutics is -2.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Atara Biotherapeutics is -2.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Atara Biotherapeutics has a P/B Ratio of 2.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Latest Insiders Trading and Volume : 

  • Insider Ownership Percentage: 4.30%
  • On 6/25/2020 CEO Pascal Touchon Sell 12,135 at average share price of $12.92 which equates to $156,784.20 in money value.
  • On 4/6/2020 Insider Joe Newell Sell 657 at average price of  $7.94 with total value of : Not Data Available
  • On 3/27/2020 Insider Joe Newell Sell 2,740 at average price of  $9.17 with total value of : $25,125.80

Analyt at Evercore ISI other ratings :

Latest rating for Atara Biotherapeutics by other brokers:

  • 6/30/2020 – 4Licensing is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $48.00 price target on the stock.
  • 6/29/2020 – Warner Music Group is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $36.00 price target on the stock.
  • 6/29/2020 – Chart Industries was upgraded by analysts at Evercore ISI from an “in-line” rating to an “outperform” rating. They now have a $62.00 price target on the stock.
  • 6/29/2020 – Kennedy-Wilson had its “outperform” rating re-affirmed by analysts at Evercore ISI. They now have a $21.00 price target on the stock.

Atara Biotherapeutics (NASDAQ:ATRA) Moving Average Technical Analysis

5 day Moving Average is $13.69 And 5 day price change is $1.90 (15.51%)  with average volume for 5 day average is 2,300,804. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $11.22 and 20 day price change is $3.63 (34.51%) and average 20 day moving volume is 1,616,531. 50 day moving average is $10.60  and 50 day price change is $5.95 ( 72.56%)  and with average volume for 50 days is : 1,845,420. 200 day moving average is $12.34  and 200 day price change is -$1.01 (-6.66%)  and with average volume for 200 days is : 991,086.

See More Analyst Rating at: RATING